Alkermes
NASDAQ: ALKS2 known investors
Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders. The company leverages neuroscience expertise to create treatments for patients with complex conditions that are traditionally underserved.
Investors · 2
In the news
- Alkermes to Report Second Quarter Financial Results on July 28, 2026 - BioSpacebiospace.com · 2026
- TD Cowen raises Alkermes stock price target to $57 on drug data By Investing.comin.investing.com · 2026
- Is Alkermes (ALKS) Fully Priced As Russell 2000 Index Inclusion Draws Fresh Attention? - Simply Wall St Newssimplywall.st · 2026
- Mizuho raises Alkermes stock price target to $65 on narcolepsy drug potential By Investing.cominvesting.com · 2026
- BofA downgrades Alkermes stock rating on valuation concerns By Investing.cominvesting.com · 2026
- Alkermes (ALKS) Advances Alixorexton As Valuation Debate Follows Phase 2 Narcolepsy Data - Simply Wall St Newssimplywall.st · 2026